Is lipoprotein (a) - Apheresis useful?

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 2, 2005, Pages 142-147

  Bambauer, Rolf ^a,b  

^a Institute for Blood Purification   (Germany)

^b NONE   (Germany)

Author keywords

DALI system; Heparin induced extracorporeal low density lipoprotein precipitation (HELP) system; Immunoadsorption; LDL apheresis; Lipoprotein (a); Liposorber system

Indexed keywords

CHOLESTEROL; ENDOTHELIUM DERIVED RELAXING FACTOR; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATINE;

APHERESIS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; ENDOTHELIUM; HYPERCHOLESTEROLEMIA; IMMUNOADSORPTION; ISCHEMIC HEART DISEASE; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR;

ADSORPTION; ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; HEMOPERFUSION; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOSORBENT TECHNIQUES; LIPOPROTEINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 19544371727     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1774-9987.2005.00236.x     Document Type: Conference Paper

References (68)

1. Brown MS, Goldstein JL. Familial hypercholesterolemia: a genetic defect in the low density lipoprotein receptor. N Engl J Med 1976;294:1386-90.
2. Brown MS, Goldstein JL. Lipoprotein receptor in the liver. Control signals for plasma cholesterol traffic. J Clin Invest 1983;72:743-7.
3. Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci Am 1984;251:58-66.
4. Steinmetz A, Uttermann G. Lipoprotein (a) als Risikofaktor für Arteriosklerose. Internist 1992;33:24-31. (in German)
5. Amstrong VM. Lipoprotein (a): Charakteristik eines besonderen Lipoproteins und dessen mögliche klinische Bedeutung. Therapeuische Umschau 1990;47:475-81. (in German)
6. Scanu AM. Lp (a) as a marker for coronary heart disease risk. Clin Invest Med 1991;14:35-9.
7. Hahmann HW, Schiefer HJ. Lipoprotein (a): Einer der wichtigsten Risikofaktoren für frühzeitige Atherosklerose bei Männern. Ellipse 1992;30:1-10. (in German)
8. Uttermann G. The Mysteries of Lipoprotein (a). Science 1993;246:904-8.
9. Hoof HF, Beck GJ, Skibinski CI, et al. Serum Lp (a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988;77:1238-44.
10. Lawn RM. Lipoprotein und Herzinfarkt. Spektrum Wissenschaft 1992;23:78-84. (in German)
11. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk, a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
12. Grainger DJ, Kirchenlohr HL, Metcalfe JC et al. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993;260:1655-8.
13. Grainger DJ, Kemp PR, Liu AC et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. Science 1994;370:460-2.
14. Seed M, Hoppichler F, Reavely D et al. Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494-9.
15. Scanu A, Fless G. Lipoprotein (a) heterogenecity biological relevance. J Clin Invest 1990;85:1709-15.
16. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at young age. Clin Chem 1990;36:20-3.
17. Amstrong VW, Cremer P, Eberle E et al. The association between serum Lp (a) concentration and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62: 249-57.
18. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocyteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
19. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of Lipoprotein (a) and the risk of myocardial infarction. JAMA 1993;270:2195-225.
20. Gaubatz JW, Hoogeveen RC, Hoffmann AS et al. Isolation, quantification, and characterization of a stable complex formed by Lp (a) binding to triglyceride-rich lipoproteins. J Lipid Res 2001;42:2058-68.
21. Komai N, Morishita R, Yamada S et al. Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells. Hypertension 2002;40:310-4.
22. Ducas J, Silvwersides C, Dembinski TC et al. Apolipoprotein (a) phenotypes predict the severity of coronary artery stenosis. Clin Invest Med 2002;25:74-82.
23. Breslow JL, Azrolan N, Bostom A. N-acetylcysteine and lipoprotein (a) (letter). Lancet 1992;339:126-7.
24. Kroon AA, Demacker PN, Stalenhoef AF. N-acetylcysteine and serum concentrations of lipoprotein (a). J Intern Med 1991;230:519-26.
25. Wiklund O, Fager G, Anderson A, Lundstam U, Masson P, Hultberg B. N-acetylcyteine treatment lowers plasma homocysteine but not serum lipoprotein (a) levels. Atherosclerosis 1996;119:99-106.
26. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1975;1:1208-11.
27. Borberg H, Gacskowski A, Hombach V, Oette K, Stoffel W. Treatment of familial hypercholesterolemia by means of specific immunoadsorption. J Clin Apheresis 1988;4:59-65.
28. Yokoyama S, Hayashi R, Satani M, Yamamoto A. A selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Atherosclerosis 1985;5:613.
29. Ritter MM, Sühler F, Richter W, Schwandt P. Short and long-term effects of LDL-apheresis on lipoprotein (a) serum levels. Clin Chim Acta 1990;195:9-16.
30. Seidel D. The H.E.L.P. system: An efficient and safe method of plasma therapy in the treatment of severe hypercholesterolemia. Ther Umsch 1990;47:514-9.
31. Bambauer R, Hahmann H. Plasmapherese-Technik und vergleichende Betrachtung der verschiedenen Verfahren im Hinblick auf die extrakorporale LDL-Elimination. Dialyse J 1990;32:28-36. (in German)
32. Olbricht CJ. Extrakorporale Elimination von LDL-Cholesterin durch Apherese. Dtsch Med Wochenschr 1991;116:25-30. (in German)
33. Bambauer R, Schiel R, Latza R. Current Topics on Low-Density Lipoprotein Apheresis. Ther Apher 2001;5:293-300.
34. Borberg H. Results of an open, longitudinal multicenter LDL-apheresis trial. Transfus Sci 1990;20:83-94.
35. Schmaldienst S, Banyai S, Stulnig TM et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolemia. Atherosclerosis 2000;15:493-9.
36. Bambauer R. Low-Density Lipoprotein Apheresis: Clinical Results with Different Methods. Artif Organs 2002;26:133-9.
37. Pokrovsky SN, Adamova IY, Afanasieva OY, Benevolenkskaya GF. Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study. Artif Organs 1991;15:136-9.
38. Pokrovsky SN, Sussekow AV, Afanasieva OY, Adamova IY, Laykishev AA, Kukharchuk AV. Extracorporeal Immunoadsorption for the specific removal of lipoprotein (a) (Lp (a) apheresis): preliminary clinical data. Chem Phys Lipids 1994;67/68:323-30.
39. Ullrich H, Lackner KJ, Schmitz G. Lipoprotein (a) apheresis in severe coronary heart disease: an immunoadsorption method. Artif Organs 1998;22:135-9.
40. Bambauer R, Schiel R, Latza R. Low Density Lipoprotein Apheresis in Treatment of Hyperlipidemia: Experience with Four Different Technologies. Ther Apher 2000;4:213-7.
41. Wieland H, Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lipid Res 1983;24:904.
42. Amstrong VW, Schleef J, Thiery J et al. Effect of HELP-LDL apheresis on serum concentrations of human lipoprotein (a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989;19:235-40.
43. Schuff-Werner P, Gohlke H, Bartmann U et al. The HELP-LDL apheresis Multicenter Study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
44. Seidel D, Amstrong VW, Schuff-Werner P for the HELP Study Group. The HELP-LDL apheresis multicenter study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest 1991;21:375-83.
45. Jaeger BR, Meiser B, Nagel D et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation 1997;96:II, 154-8.
46. Jaeger BR, Seidel D. Hyperlipoproteinemia and LDL apheresis. Clinical experiences with the HELP system. Herz 2001;26:531-44.
47. Blessing F, Wang Y, Walli AK, Seidel D. Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease. Transfus Apher Sci 2004;30:255-60.
48. Wang Y, Blessing F, Walli AK, Uberfuhr P, Fraunberger P, Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulation proinflammatory and procoagulatory markers. Atherosclerosis 2004;175:145-50.
49. Mabuchi H, Michishita T, Mitsuaki T et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL-continuous apheresis). Atherosclerosis 1987;68:233-41).
50. Yamamoto A, Kawaguchi A, Harada-Shiba M, Tsushima M, Kojima S. Apheresis technology for prevention and regressions of atherosclerosis: an overview. Ther Apher 1997;1:233-41.
51. Agishi T, Wood W, Gordon B. LDL apheresis using the Liposorber LA 15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia. Curr Ther Res 1994;55:879-904.
52. Kroon AA, Aengevaeren RM, van der Werf T et al. LDL apheresis Atherosclerosis Regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
53. Gordon BR, Saal SD. Clinical experience and future directions for low-density lipoprotein apheresis in the United States. Ther Apher 1997;1:1249-52.
54. Bambauer R, Olbricht CJ, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: Clinical result. Ther Apher 1997;1:242-8.
55. Stefnutti C, Di Giacomo S, Vivenzio A et al. Low-density lipoprotein apheresis in a patient aged 3.5 years Acta Paediatr 2001;90:694-701.
56. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG. Efficacy and safety of a new whole-blood lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003;27:1116-22.
57. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993;17:640-2.
58. Bosch T, Schmidt B, Kleophas W et al. LDL hemoperfusion: a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with the whole human blood. Artif Organs 1997;21:977-82.
59. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W. LDL hemoperfusion: a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Arif Organs 1997;21:1060-5.
60. Jansen J, Banyai S, Schmaldienst S et al. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL apheresis system for the treatment of familial hypercholesterolemia. Wien Klein Wochenschr 2000;112:61-9.
61. Inoue K, Bambauer R. Evaluation of microparticles released from an adsorber used for low density lipoprotein apheresis. ASAIO J 1998;44:M 470-4.
62. Bosch T, Lennertz A, Schenzle D, Dräger J. Direct adsorption of lipoprotein (DALI) group. Direct adsorption of low-density lipoprotein and lipoprotein (a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. J Clin Apher 2002;17:161-9.
63. Wendler T, Schilling R, Lennertz A et al. Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study. J Clin Apher 2003;18:157-66.
64. Bosch T, Keller C. Clinical effects of direct adsorption of lipoprotein apheresis: beyond cholesterol reduction. Ther Apher Dial 2003;7:341-4.
65. Thompson GR, Maher VMG, Matthews S et al. Familial Hypercholesterolemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.
66. Kostner GM, Krempler F. Lipoprotein (a). Curr Opin Lipidol 1992;3:279-84.
67. Thiery J, Seidel D. Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Curr Opin Lipidol 1988;9:521-6.
68. Bosch T, Thiery J, Gurland HJ, Seidel D. Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and hemodialysis in patients with hypercholesterolemia and end-stage renal failure. Nephrol Dial Transplant 1993;8:1350-8.